LX1001 Long-Term Follow-up (NCT05400330) - Gene Therapy for APOE4 Homozygote AD

📖 Wiki Page

clinical1451 wordssynced 2026-04-02

LX1001 Long-Term Follow-up Study (NCT05400330)

Overview

flowchart TD LX1001_Long_Term_Follow_up__NC["LX1001 Long-Term Follow-up NCT05400330 - Gene Th"] LX1001_Long_Term_Follow_up__NC["Long-Term"] LX1001_Long_Term_Follow_up__NC -->|"related to"| LX1001_Long_Term_Follow_up__NC style LX1001_Long_Term_Follow_up__NC fill:#81c784,stroke:#333,color:#000 LX1001_Long_Term_Follow_up__NC["Follow-up"] LX1001_Long_Term_Follow_up__NC -->|"related to"| LX1001_Long_Term_Follow_up__NC style LX1001_Long_Term_Follow_up__NC fill:#81c784,stroke:#333,color:#000 LX1001_Long_Term_Follow_up__NC["Study"] LX1001_Long_Term_Follow_up__NC -->|"related to"| LX1001_Long_Term_Follow_up__NC style LX1001_Long_Term_Follow_up__NC fill:#81c784,stroke:#333,color:#000 style LX1001_Long_Term_Follow_up__NC fill:#4fc3f7,stroke:#333,color:#000

This Phase 1 long-term follow-up (LTFU) study is evaluating the extended safety profile of LX1001, an adeno-associated virus (AAV) serotype rh.10 gene therapy vector expressing human [APOE2](/entities/apoe2), in participants who are homozygous for the [APOE4](/genes/apoe) allele and have been diagnosed with [Alzheimer's disease](/diseases/alzheimers-disease) (AD). LX1001 was previously administered in the parent study [NCT03634007](/clinical-trials/nct03634007-lx1001-phase-1-2), and this LTFU study tracks participants for up to 260 weeks (5 years) post-administration.

...

LX1001 Long-Term Follow-up Study (NCT05400330)

Overview

Mermaid diagram (expand to render)

The therapeutic rationale is that delivering the [APOE2](/entities/apoe2) gene directly to the central nervous system via intrathecal injection converts the APOE isoform profile from APOE4 (the strongest genetic risk factor for late-onset AD) toward APOE2, which is associated with significantly reduced AD risk and neuroprotective effects.

Trial Details

| Field | Value |
|-------|-------|
| NCT ID | NCT05400330 |
| Status | Active, not recruiting |
| Phase | Phase 1 |
| Study Type | Interventional |
| Allocation | Non-randomized (single group) |
| Intervention Model | Single arm (LTFU of prior treatment) |
| Masking | None (open-label follow-up) |
| Enrollment | 10 participants |
| Sponsor | Lexeo Therapeutics |
| Collaborators | Alzheimer's Drug Discovery Foundation, Weill Cornell Medicine |
| Start Date | May 2023 (actual) |
| Primary Completion | November 2028 (estimated) |
| Locations | PPD Orlando Research Unit (Florida), Duke University (North Carolina) |

Scientific Rationale

APOE4 Homozygosity as Highest Genetic Risk

Homozygous [APOE4](/genes/apoe) carriers represent the highest-risk population for Alzheimer's disease[@sullivan2011]:

APOE4/4 homozygotes have a 10-12× increased risk of AD compared to APOE3/3
APOE4 homozygous prevalence: ~1-2% of the general population, but ~10-15% of all AD cases
Earlier onset: APOE4/4 carriers develop AD symptoms approximately 5-10 years earlier than APOE3/3 carriers
APOE4 pathophysiology: reduced amyloid clearance, increased tau pathology, impaired lipid transport, blood-brain barrier dysfunction, and heightened neuroinflammation

APOE2 Neuroprotection

The [APOE2](/entities/apoe2) isoform (encoded by the APOE ε2 allele) is associated with:

Reduced AD risk: APOE2 carriers have ~40-50% lower risk of AD compared to APOE3/3
Enhanced amyloid clearance: APOE2 more effectively promotes Aβ degradation and transport
Improved synaptic integrity: Better support of dendritic spine maintenance and neuronal repair
Anti-inflammatory properties: Reduced microglial activation and cytokine production

Gene Therapy Approach

LX1001 delivers a functional copy of the human [APOE2](/entities/apoe2) gene directly to the CNS via intrathecal AAVrh.10 administration, enabling persistent expression of APOE2 protein in the cerebrospinal fluid and brain parenchyma. This approach bypasses the blood-brain barrier delivery challenge and achieves therapeutic levels that cannot be attained with recombinant protein or small molecule approaches.

Intervention

LX1001 Gene Therapy Vector

| Parameter | Value |
|-----------|-------|
| Agent | AAVrh.10hAPOE2 (LX1001) |
| Type | Adeno-associated virus serotype rh.10 |
| Gene Delivered | Human APOE2 complementary DNA (cDNA) |
| Route of Administration | Intrathecal injection |
| Parent Study Doses | Cohort 1: 1.4×10^10 gc/mL CSF; Cohort 2: 4.4×10^10 gc/mL CSF; Cohort 3: 1.4×10^11 gc/mL CSF; Cohort 4: 1.4×10^14 gc (fixed dose) |

AAVrh.10 Serotype Rationale

The AAVrh.10 serotype was selected for its favorable CNS tropism and reduced off-target distribution[@tai2017]. Compared to AAV9 (more commonly used for CNS applications), AAVrh.10 demonstrates:

High transduction efficiency in neurons and glia
Lower prevalence of pre-existing neutralizing antibodies in human populations
Efficient blood-brain barrier penetration when delivered directly to CSF

Eligibility Criteria

Inclusion Criteria

Prior treatment: Participants must have received LX1001 in study [NCT03634007](/clinical-trials/nct03634007-lx1001-phase-1-2)

Age: 50 years or older

Diagnosis: APOE4 homozygotes with clinical diagnosis ranging from MCI due to AD to dementia due to AD

Exclusion Criteria

Significant comorbidities: Any clinically significant medical condition that, in the investigator's opinion, would pose unacceptable risk to participant safety

Data privacy: Participants must agree not to post personal medical data or study information online, including on social media sites, until all LX1001 clinical studies (including this LTFU) have completed

Outcome Measures

Primary Endpoints

| Measure | Time Frame | Description |
|---------|------------|-------------|
| Incidence of treatment-emergent adverse events | 260 weeks | All emergent adverse events collected and categorized |
| Incidence of serious adverse events | 260 weeks | All serious adverse events documented and graded |

Secondary Endpoints

| Measure | Time Frame | Description |
|---------|------------|-------------|
| CSF APOE isoform conversion | Up to 260 weeks | Conversion of CSF APOE isoforms from APOE4 to APOE2-APOE4 profile |
| Amyloid PET scan | Up to 260 weeks | Florbetapir PET quantification of cerebral amyloid burden |
| CSF biomarkers | Up to 260 weeks | Aβ42, Aβ42/Aβ40 ratio, total tau (T-tau), phospho-tau (P-tau) |
| Quantitative MRI | Up to 260 weeks | Volumetric MRI, white matter integrity, cortical thickness |
| Cognitive and clinical assessment | Up to 260 weeks | Standardized AD cognitive batteries (specific instruments vary) |
| Tau PET scan | Up to 260 weeks | Flortaucipir PET for tau pathology burden (LX1001-01 Cohorts 3 and 4 only) |

Parent Study: NCT03634007

The parent Phase 1/2 study established LX1001 safety and dosing. Key details:

| Field | Value |
|-------|-------|
| NCT ID | NCT03634007 |
| Status | Completed (November 2024) |
| Phase | Phase 1/Phase 2 |
| Enrollment | 15 participants |
| Doses tested | 4 ascending dose levels (1.4×10^10 to 1.4×10^14 gene copies) |
| Design | Open-label, sequential cohort, dose-escalation |

Parent Study Eligibility Highlights

APOE4 homozygotes aged 50+
MCI due to AD or mild-to-moderate dementia due to AD
CSF biomarkers consistent with AD pathology
No active anti-amyloid therapy (e.g., aducanumab, lecanemab)
Serum neutralizing anti-AAVrh10 titer <1:100

Parent Study Locations

K2 Medical Research (Maitland, Florida)
PPD Orlando Research Unit (Orlando, Florida)
Weill Cornell Medicine (New York, New York)
Duke University (Durham, North Carolina)

Mechanism of Action

APOE2 Expression and Neuroprotection

Following intrathecal administration, LX1001 transduces cells in the central nervous system (primarily ependymal cells, meningeal cells, and possibly neurons and glia), leading to sustained APOE2 protein expression in the CSF. The therapeutic mechanism involves:

LX1001 (AAVrh.10hAPOE2) intrathecal administration
↓
Transduction of CNS cells (ependymal, meningeal, neurons, glia)
↓
Persistent APOE2 protein expression in CSF and brain parenchyma
↓
Isoform conversion: APOE4 → APOE2/APOE4 heterozygote profile in CSF
↓
Neuroprotective effects:

Enhanced Aβ clearance and degradation
Reduced tau phosphorylation and aggregation
Improved synaptic function and neuronal repair
Decreased neuroinflammation
Preserved blood-brain barrier integrity

↓
Slowed/arrested disease progression in APOE4 homozygotes

Key Molecular Mechanisms

APOE2 expression provides neuroprotection through multiple pathways[@kelleher2023]:

Amyloid clearance: APOE2 more efficiently binds Aβ and promotes microglial-mediated degradation and perivascular transport

Lipid transport: APOE2 supports lipid homeostasis in the brain, maintaining neuronal membrane integrity and synaptic function

Anti-inflammatory: APOE2 reduces microglial activation and pro-inflammatory cytokine production

BBB protection: APOE2 preserves blood-brain barrier integrity, reducing vascular contributions to neurodegeneration

Tau modulation: APOE2 reduces tau pathology through mechanisms involving reduced kinase activity and enhanced phosphatase function

Clinical Significance

First Gene Therapy for APOE4 Homozygotes

LX1001 represents a novel therapeutic approach targeting the fundamental genetic cause of AD in the highest-risk patient population. Unlike monoclonal antibodies that target amyloid downstream, LX1001 addresses the upstream APOE4 risk by converting the isoform profile toward a protective state.

Advantages Over Antibody Approaches

Disease-modifying: Gene therapy provides persistent (multi-year) APOE2 expression rather than periodic antibody administration
APOE4-specific: Direct targeting of the genetic risk factor rather than general amyloid clearance
Combinable: Could potentially be combined with anti-amyloid or anti-tau therapeutics for synergistic effects
BBB-independent: Intrathecal delivery bypasses blood-brain barrier, achieving high CNS concentrations

Challenges and Considerations

Invasive delivery: Requires lumbar puncture/intrathecal administration
Long-term safety: 5-year LTFU is essential to monitor for delayed adverse events
Population specificity: Only applicable to APOE4 homozygotes (~1-2% of population)
Unknown efficacy: This LTFU will provide early signals of biomarker and clinical effects

Cross-References

[APOE Gene and Alzheimer's Risk](/proteins/apoe)
[APOE2 Neuroprotection](/entities/apoe2)
[Gene Therapy for Alzheimer's Disease](/mechanisms/gene-therapy-alzheimers)
[APOE4 Homozygotes](/mechanisms/apoe4-homozygosity)
[AAV Vector Delivery to CNS](/mechanisms/aav-cns-delivery)
[Intrathecal Drug Delivery](/mechanisms/intrathecal-delivery)
[Alzheimer's Disease Therapeutics](/therapeutics/alzheimers-disease-therapeutics)
[Parent Trial: NCT03634007 - LX1001 Phase 1/2](/clinical-trials/nct03634007-lx1001-phase-1-2)

External Links

[ClinicalTrials.gov - NCT05400330 (LTFU Study)](https://clinicaltrials.gov/study/NCT05400330)
[ClinicalTrials.gov - NCT03634007 (Parent Study)](https://clinicaltrials.gov/study/NCT03634007)
[Lexeo Therapeutics - LX1001 Pipeline](https://www.lexeotx.com/pipeline)
[Alzheimer's Drug Discovery Foundation - Gene Therapy Program](https://www.alzdiscovery.org/)

References

[NCT05400330 - Long-Term Follow-up of Gene Therapy for APOE4 Homozygote Alzheimer's Disease](https://clinicaltrials.gov/study/NCT05400330)

[NCT03634007 - Gene Therapy for APOE4 Homozygote of Alzheimer's Disease](https://clinicaltrials.gov/study/NCT03634007)

[Rosenberg et al., AAV gene therapy for APOE4 homozygote Alzheimer's disease (2022)](https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/trpi.20220004)

[Kelleher et al., APOE2 neuroprotective mechanisms and gene therapy potential (2023)](https://pubmed.ncbi.nlm.nih.gov/36965941/)

[Sullivan et al., APOE genotypes and AD beta-amyloid deposition (2011)](https://pubmed.ncbi.nlm.nih.gov/21911610/)

[Tai et al., AAVrh.10 serotype for CNS gene therapy (2017)](https://pubmed.ncbi.nlm.nih.gov/27852111/)

📖 View canonical wiki page →